Connect with us

Science

What COVID is teaching doctors about the relationship between viruses and cancer

Published

on

What COVID is teaching doctors about the relationship between viruses and cancer

In early 2022, around the time the Omicron variant started driving a new surge in COVID-19 cases, researchers at James DeGregori’s University of Colorado Anschutz lab noticed something unusual: When lab mice with dormant breast cancer cells were infected with either influenza or SARS-CoV-2, the animals were significantly more likely to develop aggressive lung tumors.

What’s true for a mouse isn’t always true for a human. But when the team examined healthcare databases, they were surprised to find that something similar appeared to be going on in the human population.

Analysis of records from the U.K. Biobank showed that cancer survivors who contracted COVID in 2020 — when the virus was new and no vaccine was available — were significantly more likely to die of recurring cancer than patients who didn’t get the virus, particularly within the year after their COVID infection.

Analysis of a separate U.S. breast cancer database found that breast cancer patients in remission who got COVID were significantly more likely to develop metastatic lung tumors than patients who did not contract the virus.

Advertisement

The University of Colorado researchers couldn’t analyze influenza’s effects as thoroughly — most flu infections don’t make it into medical charts, as patients often ride out routine cases at home. They also weren’t able to take into account whether the severity of a patient’s COVID infection influenced the likelihood of a cancer recurrence. But COVID’s novelty gave the team the data it needed to track the effects of viral inflammation on cancer recurrence. Their results were published last year in the journal Nature.

“When [cancer] comes back, it comes back with a fury,” DeGregori said. “We think that these virus infections can be almost like fuel for the fire.”

Unwelcome as COVID’s emergence was, the sheer scale of its spread has vastly deepened science’s understanding of the ways that viruses can continue to affect a human body long after the initial illness has passed.

Scientists need a critical mass of data to be able to identify statistically significant patterns. In the case of a global pandemic “where the whole population gets infected, basically you have a denominator of 7 billion people,” said Dr. Stanley Perlman, a University of Iowa microbiologist who studies coronaviruses.

The rapid increase in patients suffering from long COVID supercharged research on post-viral syndromes — the complex collection of lingering symptoms doctors have long observed in some patients infected with pneumonia, flu or other viruses.

Advertisement

Now, as more years of post-pandemic data have accumulated, scientists are also able to look more closely at the complicated relationship between COVID and cancer, a disease that takes significantly longer to make itself known.

“This is something that merits more attention,” said Dr. Aditya Bardia, director of Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center. Bardia’s lab has also observed associations between COVID infection and breast cancer recurrence; that research has not yet been submitted for peer review.

There isn’t sufficient evidence to indicate that COVID is an oncogenic, or cancer-causing, virus, a half-dozen researchers contacted for this article said. The virus has some significant structural differences from known oncogenic viruses such as human papilloma virus, which is linked to cervical cancer, and hepatitis B and C, which are associated with liver cancer.

But the pandemic has left some evidence that viral infection may play a role in reawakening dormant cancer cells present in a patient’s body before infection.

“COVID and influenza do not cause cancer under themselves, but if you have cancer and you have dormant cancer cells that are normally under control by your immune system, getting a severe case of COVID can help reactivate those existing cancers,” said Dr. Patrick Moore, a virologist and epidemiologist at the University of Pittsburgh.

Advertisement

A sharp increase in metastatic breast cancer cases in the pandemic’s early years was largely attributed to care delayed by pandemic restrictions, rather than a real increase in incidence.

More recent work suggests that “it’s not just the logistics of the pandemic, but it’s really something inherent to infection” behind the association with cancer recurrence, said Melanie Ott, director of the Gladstone Institute of Virology and a professor of medicine at UC San Francisco.

The effect isn’t specific to COVID, as DeGregori’s Nature paper shows, Ott pointed out. One of the body’s natural defense mechanisms against a virus like COVID or influenza is the release of cytokines, proteins that act as chemical messengers helping to coordinate the immune system’s response.

But in some cases of severe infection, the immune system can overcorrect and send out an excess amount of these proteins, a serious and potentially fatal reaction called a cytokine storm.

Research in the early months of the pandemic showed that patients with severe COVID who died or required hospitalization were much more likely to have runaway levels of cytokines, including a particular protein called interleukin-6, or IL-6.

Advertisement

Chronically high IL-6 levels have also been linked to recurrence and metastasis of multiple types of cancer.

DeGregori’s team found that breast cancer cells in mice whose dormant cancers returned after a COVID infection reactivated in response to high levels of IL-6. Their research couldn’t prove that the same biological process happens in humans, DeGregori said. But the fact that a review of real-life patient data showed a high correlation between COVID infection and cancer recurrence makes him think they are on to something.

It’s not a settled question, even among the paper’s authors. Dr. Doug Wallace, director of the Center for Mitochondrial and Epigenomic Medicine at Children’s Hospital of Philadelphia and a co-author on the Nature paper, said he has a “slightly different interpretation” of the data.

IL-6 also inhibits mitochondria, the parts of a cell that generate energy. Wallace thinks that this suppression of the cells’ powerhouses is actually what’s encouraging cancer growth. (Mitochondrial dysfunction is also a prime suspect in the cause of long COVID.)

Other viruses shut down mitochondrial function too, Wallace said. SARS-CoV-2 seems to be particularly good at it, which could be the reason an infection leads to the lingering misery of long COVID in some people or an unexpected recurrence of cancer in others.

Advertisement

Researchers stressed that this area of study is still in its early days, and there is no definitive causal link between COVID infection and cancer recurrence.

“It’s fair to say that [COVID infection] could be added to the long list of theoretical reasons that cancer might be more likely to come back, [but] I’m on the skeptical side of all things. Prove it to me,” said Dr. Eric Winer, director of the Yale Cancer Center. “This is one where I’d say, interesting finding, let’s look more.”

The evidence to date suggests simply that the question is worthy of more study, researchers said. If there is any action people with vulnerable immune systems should take as a result, it’s to continue reasonable precautions against viral infections of all kinds.

“There’s a very, very, very compelling reason for those patients who have chronic diseases to avoid getting a severe case of influenza or COVID or respiratory syncytial [virus] — all of these diseases for which good, safe, effective vaccines exist,” Moore said.

Advertisement

Science

China Launches Reusable Rocket in Race With SpaceX

Published

on

Video released by Chinese state media shows a state-owned aerospace company launching a rocket and recovering part of it on Friday. The successful launch of a reusable rocket was a major step for China toward challenging SpaceX’s satellite internet dominance.

Continue Reading

Science

Nobel Prize winner leaving UC Berkeley for new role in China

Published

on

Nobel Prize winner leaving UC Berkeley for new role in China

Nobel Prize recipient Omar Yaghi is leaving his role at UC Berkeley to lead the development of a new artificial intelligence institute at Tsinghua University in Beijing, the Chinese university announced.

Yaghi will head the AI Chemistry and Materials Research Institute at Tsinghua, where he was appointed an honorary professor in 2022. Known as AIMATRY (AI × Materials × Chemistry), the new center will focus on material design and synthesis through artificial intelligence, according to a statement from the university.

In 2025, Yaghi shared the Nobel Prize in chemistry with Susumu Kitagawa of Kyoto University and Richard Robson of the University of Melbourne for their development of metal-organic frameworks, a type of super-porous material in which metal ions and carbon-based molecules combine to form crystals with exceptionally large surface areas.

The material has the potential to combat climate change by capturing and storing carbon or other pollutants, and by extracting water from the atmosphere in water-scarce areas. Upon awarding the prize, a member of the Nobel committee likened the technology’s ability to store enormous amounts of stuff in seemingly compact spaces to Hermione Granger’s enchanted handbag in the Harry Potter series.

Yaghi’s Irvine-based company, Atoco, has said it will start taking orders later this year for its technology that harvests water from the air.

Advertisement

A representative for Yaghi said he was not yet available to respond to questions.

China is one of several countries that has been actively recruiting scientists from the U.S., where the Trump administration has slashed science funding, suspended research grants, fired science advisors and tightened immigration restrictions.

“For many, many years, our funding was very competitive; if you worked hard and you were doing good research, you would get funding,” Yaghi said of the U.S. in an interview with Scientific American earlier this year. “The current state is not so encouraging because of the cutting back on grants and support of science by the very agencies that many university researchers rely on.”

Yaghi was born in Jordan to Palestinian refugees, and immigrated to the U.S. when he was 15 to study.

“We’ve learned over and over in human civilization that scholars can move across borders,” Yaghi told the New York Times last year. “This is how knowledge spread and how vast regions of the world lifted themselves out of poverty.”

Advertisement
Continue Reading

Science

Trump administration seeks to limit federal funding that doesn’t ‘advance’ presidential policies

Published

on

Trump administration seeks to limit federal funding that doesn’t ‘advance’ presidential policies

A new rule proposed by the White House Office of Management and Budget would fundamentally overhaul the way federal grants are awarded and overseen — a sweeping change that one scientific society said “would all but end the use of scientific merit in the selection of grants and programs across the government.”

Proposed in late May, the rule would give political appointees unprecedented control over federal grants for research, education and infrastructure, and specifies that government funds can only be spent on projects “aligned with administration policies and priorities,” according to a copy of the proposed rule.

The rule would also restrict research topics, limit U.S. scientists’ ability to collaborate with colleagues in other countries and make it easier for the government to suspend or cancel grants at any time.

The changes are intended to improve “transparency, accountability, and oversight for Federal awards” while “ensuring that American tax dollars are not wasted or misused,” according to the White House office.

But critics say that if the rule is implemented, the final sign-off for grants will no longer be in the hands of subject-matter experts within individual agencies, but in those of political appointees.

Advertisement

“This touches all parts of American life,” said Dr. Eric Rafla-Yuan, a psychiatrist who practices at the Veterans Administration and San Diego County’s psychiatric hospital.

“Control of how all of the federal grants and programs are funded will fall under a small group of highly partisan individuals who would have very few limits on how they spend these billions of taxpayer dollars,” said Rafla-Yuan, who also chairs the Committee to Protect Public Mental Health advocacy group. “This touches everyone’s life, even if they don’t realize it.”

OMB published the proposed rule May 29, opening a 45-day comment period that closes July 13.

Opposition to the proposed rule has mobilized multiple sectors of society. Professional groups representing cancer researchers, civil engineers, county governments, medical schools, housing agencies, city and municipal governments, nonprofits and others have publicly expressed concerns about potential consequences.

By midday Thursday, the Federal Register logged nearly 100,000 comments about the proposal, many of them expressing concern.

Advertisement

“I understand the need for oversight, fiscal responsibility, and accountability. That is not the issue,” wrote Jack Feldman, a neuroscientist who holds the David Geffen School of Medicine Chair in Neuroscience at UCLA. “The issue is whether scientific research is to be judged by scientific merit, or whether it can be approved, denied, or terminated according to broad political criteria that may change from one administration to the next.”

Crucially, the rule converts policies governing federal grants from “guidance” into binding regulations that all agencies would be required to follow. It would give political appointees power to override federal agencies’ merit-based reviews and mandate that a political appointee review decisions to ensure that all awards “demonstrably advance the President’s policy priorities.”

The elevation of political appointees in what were previously merit-based decisions has alarmed many scientists.

“The proposed rule changes would all but end the use of scientific merit in the selection of grants and programs across the government,” read a statement from the Planetary Society, a nonprofit dedicated to space research.

Researchers and science groups have also expressed concern about a section of the rule prohibiting the promotion of “theories of disparate-impact liability” — a legal concept that refers to policies that appear neutral but cause disproportionate harm to certain groups.

Advertisement

The section’s vague language and many loopholes could have a chilling effect on any research that studies the effects of a disease, policy or public health intervention on any specific group of people, Rafla-Yuan said.

As an example, he said, “if there’s a specific age range that is at higher risk for suicide, and we want to figure out, well, what’s going on with people that are aged 14 to 19 … we can’t do that under the wording in this rule.”

New restrictions on collaborations with scientists in other countries would hinder opportunities for U.S. researchers and limit innovation, said Joanne Padrón Carney, chief government relations officer for the American Assn. for the Advancement of Science.

“Science is a global enterprise. Especially in biomedical and public health fields, diseases don’t care about borders or government policies,” she said.

California’s congressional delegation sent a letter Wednesday asking OMB to rescind the proposal, outlining concerns about its impact on scientific innovation, U.S. competitiveness and the fiscal stability of local governments, many of which rely on federal grants for local services.

Advertisement

The proposed rule grants the federal government broad powers to suspend or cancel grants for any reason, introducing “unprecedented unpredictability into local governance,” the lawmakers wrote, “leaving vital infrastructure projects unfinished and abandoning vulnerable populations who rely on these services.”

Republican Sen. Susan Collins has also asked the White House to withdraw certain parts of the letter and extend the public comment period, saying the proposed rule as written would “harm small and rural communities, undermine scientific and biomedical research, and conflict with Congress’ control over the federal funding process.”

Continue Reading
Advertisement

Trending